Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00875446 · ClinicalTrials.gov registry record · Phase 1
First Time in Human Study of GSK1223249 in Amyotrophic Lateral Sclerosis
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 76
- Enrollment target
NCT00875446 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 76 participants.
The verdict
NCT00875446, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 76 participants
- Enrollment target
Study Summary
The drug being tested in this study is GSK1223249. It is being developed by GlaxoSmithKline to treat symptoms in patients with Amyotrophic Lateral Sclerosis (ALS). The drug works by inhibiting the protein that prevents nerve growth. This will be the first time the drug will be given to man. The trial is expected to involve approximately 76 patients. The study objective is to investigate the tolerability, safety and the way the body handles GSK1223249 after a range of single doses or repeat dose escalation in patients with ALS.
Interventions
- DRUG PLACEBO
- DRUG GSK1223249
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2009-05-13 |
| Est. Completion | 2011-09-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00875446
The ClinicalTrials.gov registry entry for NCT00875446 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PLACEBO is the first listed.
NCT00875446 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00875446 about?
NCT00875446 is a clinical study titled "First Time in Human Study of GSK1223249 in Amyotrophic Lateral Sclerosis". The drug being tested in this study is GSK1223249. It is being developed by GlaxoSmithKline to treat symptoms in patients with Amyotrophic Lateral Sclerosis (ALS). The drug works by inhibiting the protein that prevents nerve growth. This will be the first time the drug will be given to man. The tr...
What is the current status of trial NCT00875446?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 76 participants. The study started on 2009-05-13. Estimated completion is 2011-09-09.
What interventions are being tested in trial NCT00875446?
The interventions under investigation include: PLACEBO (DRUG), GSK1223249 (DRUG).
Who is sponsoring clinical trial NCT00875446?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.